Market Highlights:
Global Migraine Drugs Market Research Report: By Type (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices), By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2025
According to MRFR analysis, the global migraine drugs market is expected to register a CAGR of 5.9% during the forecast period of 2019 to 2025 and was valued at USD 4.4 billion in 2018.
Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels. Approximately 12% of the US population suffered from migraine headaches in 2018. The treatment of migraine headaches is eased by the administration of preventive medications, to avoid migraine attacks and abortive medications to relieve strong and periodic pain.
The growth of the global migraine drugs market is driven by various factors such as an increasing global geriatric population, rising prevalence of migraine, growing awareness about migraine in developing economies, rising R&D investment for the development of innovative drugs for the treatment of migraine, and increasing demand for better treatment methods for migraine. However, stringent government regulations, high investment required for drug research & development, and side-effects of medications prescribed for migraine are the factors that are expected to limit the growth of the global migraine drugs market during the forecast period.
Market Key Players:
Some of the key players in the global migraine drugs market are Allergan Plc (Ireland), Alder Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), AstraZeneca Plc (UK), Johnson & Johnson Services, Inc. (US), Amgen Inc (US), Eli Lilly and Company, and eNeura Inc.
Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8379
Segmentation:
The global migraine drugs market has been segmented based on type, treatment, drug class, and end user.
The global migraine drugs market has been segmented, on the basis of migraine-type into episodic migraine and chronic migraine.
The global migraine drugs market has been segmented, on the basis of treatment type, into, acute, preventive, neuromodulation, and others.
The acute segment is expected to hold the majority share of the market as the prevalence of acute migraine is high, and most of the drugs manufactured by major companies are for the treatment of acute migraine.
The global migraine drugs market has been segmented, on the basis of drug class, into beta-blockers, Angiotensin Blockers, tricyclics, anticonvulsants, triptans, and others.
Triptons are the most preferred type of drugs class for migraine patients due to its high efficacy. It holds the major share in the market by drug class. Approximately 80% of the migraine patients are treated with Triptans, and more than 40% of the patients suffering from cardiovascular diseases with migraine were treated with triptans in 2018.
The market on the basis of end user has been segmented into hospitals and clinics, research and academic institutes, and others. The hospitals and clinics segment is expected to hold the largest share of the market as they are primary centers of treatment for the patient. The retail pharmacy segment offers over the counter (OTC) and prescription migraine drugs though a chain of pharmacies globally. Other end users include online pharmacy segment that offers OTC migraine drugs through e-commerce platforms.
Regional Analysis:
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to be the largest market owing to the increasing prevalence of migraine and R&D by major players in the region. For instance, in September 2018, Eli Lilly and Company launched Emgality (galcanezumab-gnlm) injection (300 mg) for the preventive treatment of migraine in adults. It is the first drug to receive Food and Drug Administration (FDA) approval for decreasing the frequency of episodic cluster headache attacks. The migraine drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
The European migraine drugs market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The migraine drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Growing geriatric population, increasing patients suffering from neurological diseases, raising awareness about migraine, government initiatives in emerging economies to provide better healthcare infrastructure, and strategic initiatives by regional and market leaders are driving the migraine market in Asia-Pacific. The Asia-Pacific region is expected to be the fastest-growing during the forecast period.
The migraine drugs market in the Middle East & Africa has been divided into the Middle East and Africa.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/migraine-drugs-market-8379
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
Migraine Drugs Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2015-2025 – Increased prevalence of migraine and increased awareness among people are the key drivers for Global Migraine Drugs Market.Migraine Drugs Market is valued around USD 1851.23 Million in 2018 and expected to reach USD 2375.62 Million by 2025 with the CAGR of 3.37% over the forecast period.
There is no solitary cure for migraines.
These symptoms are relieved by different drugs available in the market.
On the basis of country level, market of Migraine Drugs is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.Key Players for Global Migraine Drugs Market Reports–Global migraine drugs market report covers prominent players like AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., GlaxoSmithKline plc, Eli Lilly & Co., Allergan Plc., Novartis AG, Merck & Co., Inc., Valeant Pharmaceutical International, Inc., Eisai Co., Ltd., Janssen Pharmaceutical Company (Johnson & Johnson), Pfizer, Inc., Zosano Pharma Corporation, Avanir Pharmaceuticals, Inc., and others.Increase in the prevalence of Migraine and increased awareness among peopleThe commercialization and growth of global migraine drugs market over the past 25 years has been highly impactful.
Furthermore, increased demand of better treatment and technological advancement led to the development of Smartphone controlled wireless patches for the management of the migraine which is also expected to supplement the growth of migraine drugs market over the forecast period.
The growth is attributed to the high prevalence of migraine coupled with advanced healthcare facilities and high per capita income.
The Global Migraine Drugs Market size was valued at USD 1.80 billion in 2019 and is predicted to reach USD 2.44 billion by 2030, with a CAGR of 2.8% from 2020-2030.Migraine is a medical condition pertaining with primary headache disorder with symptoms such as nausea, vomiting, dry mouth, somnolence, and sensitivity to light or sound.
In some cases, patients are affected by prevalence of aura.
Migraine has no permanent cure, but migraine drugs can be used to reduce and prevent migraines.Access Full Description of this report at:-https://www.nextmsc.com/report/migraine-drugs-market Top Companies: Allergan Plc, Abbott Laboratories, AstraZeneca, Endo International Plc., Eisai Co. Ltd., Impax Laboratories, GlaxoSmithKline Plc., Johnson & Johnson, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Limited, Sanofi SA and others.According to the data provided by Migraine Trust in 2017, 1 in 7 people worldwide suffer from migraine, i.e.
2% of the total world population suffer from migraine; thereby, migraine being the third most common disease at global level.
However, side effects associated with the intake of migraine drugs are expected to restrict the growth of migraine drugs market.Request sample copy of this report at:-https://www.nextmsc.com/Migraine-Drugs-Market/request-sample The global migraine drugs market share has been analyzed based on type, route of administration, distribution channel and geography.
The preventive medicine is further divided into Anticonvulsant, Antidepressant, Beta Blocker, and others.
Global Migraine Drugs Market report published by Reports and Data offers a comprehensive analysis of the Migraine Drugs market with regards to market share, market size, revenue growth, trends and demands, drivers and restraints, competitive scenario, business landscape, and regional bifurcation.
The report also offers forecast estimation about segments and sub-segments expected to show lucrative growth over the forecast period.
The report, additionally, offers a comprehensive SWOT analysis and Porter’s Five Forces analysis to offer a better understanding of the competitive landscape of the industry.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2515The report provides a panoramic view of the market and insights that will help formulate better business decisions.
In addition to that, the study helps well-established companies and players gain a deeper understanding of the market and make informed decisions.
The report also focuses on recent strategic alliances in the market including mergers and acquisitions, joint ventures, partnerships, agreements, corporate and government deals, product launches, and brand promotions, among others.Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2515 The report aims to provide a better understanding of the market dynamics and the workings of the industry on a global level.
